Skip to main content

Advertisement

Table 1 Clinical and demographic baseline characteristics of rheumatoid arthritis patients a

From: Smoking in combination with antibodies to cyclic citrullinated peptides is associated with persistently high levels of survivin in early rheumatoid arthritis: a prospective cohort study

Patient demographics (N = 339) Level and frequency
Age, years 56.5 ± 16
Women 224 (66%)
Disease duration, months 6.2 ± 3.3
RF+ 184 (55%)
aCCP+ 169 (49%)
DAS28 5.6 ± 1.26
VAS pain, mm 45 ± 24
HAQ 1.00 ± 0.66
SHS, median (IQR) 1.7 (0 to 5)
Smoking habits  
   Never 166 (49%)
   Previous 89 (26%)
   Current 84 (25%)
Treatment at start  
   MTX 131 (39%)
   SLZ 112 (33%)
   Combination of DMARDs 3 (1%)
   No DMARDs 51 (15%)
   Prednisolone 210 (62%)
  1. aaCCP+, positive for antibodies against cyclic citrullinated peptides; DAS28, Disease Activity Score based on evaluation of 28 joints; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; MTX, methotrexate; RF+, rheumatoid factor–positive; SHS, Sharp-van der Heijde score; SLZ, sulphasalazine; VAS, Visual Analogue Scale. The values are mean ± SD or n (%) unless otherwise stated.